Medullary Thyroid Carcinoma
📧 Sign up to get email alerts when something new happens for Medullary Thyroid Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) [Phase 1, Phase 2]
LIBRETTO-001 is a Phase 1/2 trial of selpercatinib in RET fusion–positive advanced solid tumors, including non-small cell lung cancer and me…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors [Phase 1, Phase 2]
This phase 1/2 clinical trial update reports results for selpercatinib in pediatric participants with advanced solid tumors and primary CNS …
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: Study of ACC-1898 in Adult Participants With Advanced Solid Tumors [Phase 1]
Phase 1 study update for ACC-1898 in adults with advanced solid tumors; the trial is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-11-13Clinical Trial Update: Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer [Phase 2]
Phase 2 clinical trial evaluating selpercatinib given before surgery for RET-altered thyroid cancers is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-09-02Clinical Trial Update: A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer [Phase 4]
Phase 4 study evaluating two dosing regimens of cabozantinib (XL184) in progressive, metastatic medullary thyroid carcinoma; results have be…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer [NA]
A completed clinical trial evaluated 18F-PSMA PET/CT imaging in patients with medullary thyroid carcinoma.
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 study results show activity and safety of pralsetinib in RET-altered cancers, including non-small cell lung cancer and thyroid can…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. [Phase 1]
Phase 1 clinical trial evaluating the radiopharmaceutical 177Lu-PP-F11N for receptor-targeted therapy and imaging in metastatic medullary th…
-
CLINICAL_TRIALS trial_result · 2025-01-03Clinical Trial Update: Predictive Factors for Medullary Thyroid Cancer Aggressiveness
This clinical trial examines predictive factors associated with the aggressiveness of medullary thyroid carcinoma and has completed.
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
An observational trial update evaluating vandetanib in RET +/- patients with metastatic medullary thyroid carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer [Phase 3]
Phase 3 study of selpercatinib (Retevmo) in RET-mutant medullary thyroid carcinoma has results posted (June 13, 2024); the trial is currentl…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations [Phase 1, Phase 2]
A study of TPX-0046, a RET/SRC inhibitor, in adults with advanced solid tumors including non-small cell lung cancer and medullary thyroid ca…
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer [Phase 2]
Phase 2 study assessing regorafenib as second or third line therapy for metastatic medullary thyroid carcinoma; results have been posted.
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma [Phase 4]
Phase 4 trial investigating anlotinib in patients with advanced medullary thyroid carcinoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: ImmunoTEP for Patients With Medullary Thyroid Carcinoma. [Phase 1, Phase 2]
Phase 1/2 clinical trial update for ImmunoTEP in patients with Medullary Thyroid Carcinoma (completed).
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation [Phase 2]
Phase 2 study of selpercatinib (Retevmo) in adults with advanced RET-altered solid tumors, including RET fusion–positive cancers and medulla…
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) [Phase 2]
Phase 2 clinical trial update for HA121-28 tablets in medullary thyroid carcinoma, status not disclosed.
-
CLINICAL_TRIALS trial_result · 2020-12-22Clinical Trial Update: Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer [Phase 1, Phase 2]
Clinical trial update on vandetanib for children and adolescents with medullary thyroid carcinoma, including conditions related to multiple …
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: Nintedanib(BIBF1120) in Thyroid Cancer [Phase 2]
Phase 2 trial of nintedanib (BIBF1120) in thyroid cancer (medullary and differentiated thyroid cancer) has completed.
-
CLINICAL_TRIALS trial_result · 2020-02-13Clinical Trial Update: Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma [Phase 2]
Phase 2 study of sulfatinib for advanced medullary thyroid carcinoma and iodine-refractory differentiated thyroid carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-05-21Clinical Trial Update: Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) [Phase 2, Phase 3]
A study evaluating anlotinib in medullary thyroid carcinoma has completed Phase 2 and Phase 3 trials.
-
CLINICAL_TRIALS trial_result · 2018-12-21Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer [Phase 2]
Phase 2 trial evaluating sorafenib tosylate for metastatic, locally advanced, or recurrent medullary thyroid cancer; study completed with re…
-
CLINICAL_TRIALS trial_result · 2018-05-22Clinical Trial Update: Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients
A clinical trial assessing quality-of-life measurement tools in patients with medullary thyroid carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
This completed clinical trial update from the National Cancer Institute investigates molecular pathways in medullary thyroid carcinoma and c…
-
CLINICAL_TRIALS trial_result · 2017-09-15Clinical Trial Update: Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery [Phase 2]
This Phase 2 trial evaluated Sunitinib malate in iodine-refractory thyroid cancers, including differentiated and medullary subtypes. Results…